4.7 Review

Mild cognitive impairment: prevalence, prognosis, aetiology, and treatment

期刊

LANCET NEUROLOGY
卷 2, 期 1, 页码 15-21

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/S1474-4422(03)00262-X

关键词

-

资金

  1. NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051429] Funding Source: NIH RePORTER
  2. NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017950] Funding Source: NIH RePORTER
  3. NATIONAL INSTITUTE ON AGING [P30AG010129, R01AG016495] Funding Source: NIH RePORTER
  4. NHLBI NIH HHS [2R01 HL51429-04] Funding Source: Medline
  5. NIA NIH HHS [1R01 AG16495-01, 2R01 AG111101-06, P30-AG10129] Funding Source: Medline
  6. NINDS NIH HHS [5R01 NS17050, R01 NS017950] Funding Source: Medline

向作者/读者索取更多资源

Mild cognitive impairment (MCI) is a recently described syndrome that is currently thought of as a transition phase between healthy cognitive ageing and dementia. Although this notion seems to be reasonable, the general nature of the term MCI-including its many definitions-makes accurate accounting of the prevalence, prognosis, and potential benefit from treatment somewhat difficult. The differences in cognitive profile and clinical progression among individuals with MCI are generally recognised. However, recent evidence also suggests that the aetiological heterogeneity among individuals with MCI could be greater than previously reported. For example, cerebrovascular disease seems to be underestimated as a potential cause of MCI. In this review, I attempt to recognise workable definitions of MCI to discuss the prevalence, pathophysiology, prognosis, and possibilities for treatment of this disorder.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据